For selective screening determination of urinary cotinine, i.e. (S)-1-methyl-5-(3-pyridyl)-2-pyrrolidinone, the major metabolite of nicotine, the high-performance thin-layer chromatographic (HPTLC) method have been proposed. Prior the final HPTLC analysis the procedure required a solid-phase extraction (SPE) of cotinine from collected urine samples with 1-methyl-2-pyrrolidinone as an internal standard. Densitometrical quantitation of cotinine on the chromatograms have been performed with a 16-grayscale scanner using the specialized software implemented on a desktop microcomputer. The lower detection limit of cotinine was 6 microg/l allowing the method to be applied for the measurement a concentration of this compound in urine samples collected from 35 elementary schoolboys exposed on both moderate and/or significant ETS. The mean recovery of cotinine from urine samples was 93%. The mean intra-day accuracy for the analysis of cotinine in range 6-750 microg/l. including four paralell measurements, was 2.9 %. The results of cotinine measurements by proposed SPE-HPTLC procedure were used in the pilot studies for assessment of hazard from home ETS on the health status of elementary schoolboys, especially an increased risk for infectious respiratory track diseases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0731-7085(00)00402-7 | DOI Listing |
J Atten Disord
January 2025
Nutrition and Mental Health Research Group (NUTRISAM), Universitat Rovira i Virgili, Tarragona, Spain.
Exposure to heavy metals has been associated with affecting children's neurodevelopment, particularly increasing the risk of developing attention-deficit hyperactivity disorder (ADHD). The current exploratory study aims to investigate potential associations between presence of 15 different heavy metals in urine and ADHD. A total of 190 urine samples of participants from clinical and non-clinical population (non-ADHD = 66; ADHD = 124) aged between 6 and 15 years from Barcelona and Tarragona (Spain) were analysed.
View Article and Find Full Text PDFCJC Open
February 2024
CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Background: Type I myocardial infarction (T1MI) or type II myocardial infarction (T2MI) have different underlying mechanisms; however, in the setting of cardiogenic shock (CS), it is not understood if patients experience resultantly different outcomes. The objective of this study was to determine clinical features, biomarker patterns, and outcomes in these subgroups.
Methods: Patients from the CAPITAL-DOREMI trial presenting with acute myocardial infarction-associated CS (n = 103) were classified as T1MI (n = 61) or T2MI (n = 42).
Sci Rep
January 2025
Praxis Dr.Carmine, Etzelstrasse 21, Pfaeffikon SZ, 8808, Switzerland.
Spot-urinary biomarkers are crucial in medical, epidemiological, and environmental studies, but their variability due to hydration levels requires precise dilution adjustments. Traditional methods, like conventional creatinine correction (CCRC), are limited in compensating for variations in urine concentration, causing substantial inconsistencies, particularly at the extremes of the diuresis spectrum. While restricting the creatinine (CRN) range to 0.
View Article and Find Full Text PDFDrug Metab Dispos
January 2025
Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Tanimilast is an inhaled phosphodiesterase-4 inhibitor currently in phase III clinical development for treating chronic obstructive pulmonary disease and asthma. This trial aimed to characterize the pharmacokinetics, mass balance, and metabolite profiling of tanimilast. Eight healthy male volunteers received a single dose of nonradiolabeled tanimilast via powder inhaler (Chiesi NEXThaler [3200 μg]), followed by a concomitant intravenous infusion of a microtracer ([C]-tanimilast: 18.
View Article and Find Full Text PDFDrug Metab Dispos
January 2025
Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan.
Pirfenidone (PIR) is used in the treatment of idiopathic pulmonary fibrosis. After oral administration, it is metabolized by cytochrome P450 1A2 to 5-hydroxylpirfenidone (5-OH PIR) and further oxidized to 5-carboxylpirfenidone (5-COOH PIR), a major metabolite excreted in the urine (90% of the dose). This study aimed to identify enzymes that catalyze the formation of 5-COOH PIR from 5-OH PIR in the human liver.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!